New drug R3R01 targets protein leak in tough kidney diseases
NCT ID NCT05267262
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 23 times
Summary
This study tested a new drug, R3R01, in 43 people with Alport syndrome or a kidney condition called focal segmental glomerulosclerosis (FSGS) who still had protein in their urine despite standard treatment. The main goals were to check the drug's safety and see if it could reduce protein levels in urine. The study was completed, but results are not yet available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOCAL SEGMENTAL GLOMERULOSCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigative Site
Los Angeles, California, 90022, United States
-
Investigative Site
Cary, North Carolina, 27511, United States
-
Investigative Site
Dallas, Texas, 75204, United States
-
Investigative site
Boca Raton, Florida, 33431, United States
-
Investigative site
Miami, Florida, 33136, United States
-
Investigative site
Riverview, Florida, 33578, United States
-
Investigative site
Atlanta, Georgia, 30322, United States
-
Investigative site
Boston, Massachusetts, 02111, United States
-
Investigative site
Ann Arbor, Michigan, 48109-5718, United States
-
Investigative site
Minneapolis, Minnesota, 55454, United States
-
Investigative site
Cleveland, Ohio, 44195, United States
-
Investigative site
Columbus, Ohio, 43235, United States
-
Investigative site
East Providence, Rhode Island, 02914, United States
-
Investigative site
Houston, Texas, 77054, United States
-
Investigative site
Brussels, 1200, Belgium
-
Investigative site
Liège, 4000, Belgium
-
Investigative site
Paris, 75015, France
-
Investigative site
Göttingen, 37075, Germany
-
Investigative site
Amsterdam, 1105AZ, Netherlands
-
Investigative site
Nijmegen, 6525 GA, Netherlands
-
Investigative site
Leicester, LE5 4PW, United Kingdom
-
Investigative site
Nottingham, NG5 1PB, United Kingdom
Conditions
Explore the condition pages connected to this study.